TSTakeshi Senju

Takeshi Senju

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Takeshi Senju has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gemcitabine + Cisplatin + S-1 Treatment for Advanced Cholangiocarcinoma: Cost-Effective, with Better Progression-Free Survival and Objective Response Rates Versus Standard Treatment with Gemcitabine + Cisplatin + Durvalumab

    by Yusuke Morita, Rie Sugimoto, Miho Kurokawa, Yuki Tanaka, Takeshi Senju, Toshimitsu Ichimaru, Lingaku Lee, Yusuke Niina, Terumasa Hisano, Masayuki Furukawa, et al.

    Objectives: To evaluate the prognosis and costs of gemcitabine + cisplatin + S-1 (GCS) versus gemcitabine + cisplatin + durvalumab (GCD), the standard of care for advanced cholangiocarcinoma, in a prospective observational study. Methods: We enrolled 52 patients who received GCS as first-line treatment from April 2020 to April 2024 and 44 patients who received GCD from March 2023 to April 2024. Overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) were examined. Propensity score matching (PSM) was performed to balance baseline characteristics between the two groups, and OS, PFS and ORR were then analysed in the matched cohorts. Drug costs were compared until the end of treatment. Results: OS was not significantly different between GCD and GCS at 12.2 months (95% confidence interval [CI]: 7.5–16) versus 18.6 months (95% CI: 13.3–21.9) (p=0.0935). P FS was 6.26 months (95% CI: 3.2–8.8) versus 10.2 months (95% CI: 6.5–13.8) for GCD versus GCS, respectively (p=0.0151). The ORR was also better for GCD (36.5%) than for GCS (15.9%) (p=0.0234). Twenty-seven cases were included in the PSM analysis, which showed n o significant differences in OS and b etter PFS (6.3, 95% CI: 2.8–9.3 versus 11.4, 95% CI: 6.2–15.0; p=0.0142) and ORR (14.8% versus 40.7%; p=0.0309) for GCS versus GCD, respectively. The cost of GCD versus GCS was 113,472 ± 72,198 versus 4622 ± 3109 US dollars by treatment end (p=0.0001). Conclusions: GCS was significantly less expensive than GCD and showed comparable OS and better PFS and ORR.

  • Open Access

    Advances in Systemic Therapy for Hepatocellular Carcinoma and Future Prospects

    by Rie Sugimoto, Miho Kurokawa, Yuki Tanaka, Takeshi Senju, Motoyuki Kohjima, Masatake Tanaka

    The focus of treatment of hepatocellular carcinoma (HCC) has shifted significantly from local therapy to systemic drug therapy. Recently, the efficacy of drug therapy for HCC has made rapid progress. We have transitioned from eras of sorafenib monotherapy and sequential therapy with multiple tyrosine kinase inhibitors that slightly improved patient prognoses, to an era where the introduction of immunotherapy combining atezolizumab and bevacizumab has achieved further improvements in patient prognosis. The availability of highly effective drugs has expanded the range of diseases treatable by drug therapy. Additionally, instead of initiating drug therapy at advanced stages, combining it with local therapies such as transarterial chemoembolization at an earlier stage with the aim of achieving a cure has become possible, improving treatment outcomes further. Currently, the number of regimens available for HCC, including combinations of multiple drugs and local therapies, has increased, leading to numerous clinical trials. Additionally, HCC cases that were previously unresectable are now resectable after drug therapy, necessitating the establishment of a resectability classification system. This review summarizes the current evidence for drug therapy for HCC and discusses future treatment strategies, treatment combinations, and prospects.


  • Open Access

    Atezolizumab plus Bevacizumab Treatment Worsens Liver Reserve in Patients with Nafld/Nash-Associated Liver Cancer More than in Those with Non-nafld/Non-Nash-Associated Liver Cancer

    by Rie Sugimoto, Kenta Motomura, Takeaki Satoh, Yuki Tanaka, Shinsaku Yamashita, Nobito Higuchi, Toshimasa Koyanagi, Tsukasa Nakamura, Masatake Tanaka, Yuuki Azuma, et al.

    (1) Background: Although multiple studies have reported on the therapeutic effects of Atezo+Bev for the treatment of NASH-related liver cancer, few studies have focused on its effect on liver reserve. Here, we aimed to compare the changes in hepatic reserve during the Atezo+Bev treatment of NAFLD/NASH-related HCC and of non-NAFLD/non-NASH-related HCC. (2) Methods: We retrospectively compared the changes in ALBI score in 109 patients with NAFLD/NASH or non-NAFLD/non-NASH during 12 weeks of treatment with Atezo+Bev for advanced HCC between September 2019 and January 2022. PSM was performed, and the OS, PFS, and PPS of the two groups were compared. (3)Results: The ALBI after 12 weeks of Atezo+Bev treatment was significantly worse in the NAFLD/NASH group than in the non-NAFLD/non-NASH group. Analysis of the 24 propensity score-matched pairs of cases with NAFLD/NASH or non-NAFLD non-NASH yielded similar results. The prognoses of the two groups were similar with respect to OS and PFS, but the NAFLD/NASH group had a significantly shorter PPS. The 24 matched pairs had similar OS and PFS, but the PPS of the NAFLD/NASH group was shorter. (4)Conclusion: Atezo+Bev treatment may worsen hepatic reserve, and there-fore life expectancy, in patients with NAFLD/NASH-related liver cancer.